Shot: The companies expand their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets In Mar’2020, the companies collaborated for AVT02 (biosimilar, adalimumab). The collaboration targets Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh, and Pakistan The expansion deepens the partnership b/w the two companies […]Read More
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Hence, the providers are more likely to adopt biosimilars as a “reference product to biologics” possessing similar therapeutic properties The US FDA took an initiative to develop new pathways for Insulin biosimilars. Our team at PharmaShots has […]Read More
Shots: Alvotech will be responsible for the development and supply of AVT02 in selected APAC market, while DKSH will be responsible for the registration and commercialization of the therapy The alliance allows the Alvotech to gain access to DKHS’s commercial expertise, which will aid patients to get benefited with high-quality biosimilar therapies AVT02 is a […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
